Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations information was updated to include Ontario under a general Locations section, replacing the previous Ontario Locations header. The page revision was updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0. This is a minor version update and does not change the study information.SummaryDifference0.1%

- Check49 days agoChange DetectedRemoved the government funding operating-status notice from the page. The study details and other content remain unchanged.SummaryDifference0.4%

- Check71 days agoChange DetectedOnly non-substantive updates are visible, such as the last update timestamp; the core study details, eligibility criteria, endpoints, and listed locations appear unchanged.SummaryDifference0.4%

- Check92 days agoChange DetectedMajor upgrade: version bumped to v3.2.0 and a prominent funding/operating-status notice added; previous v3.1.0 deletion indicates update to the site’s status messaging.SummaryDifference3%

- Check100 days agoChange DetectedMajor update to page status and versioning: add Results Submitted, Last Update Posted (Estimated), and Revision v3.1.0; remove No Results Posted, Last Update Posted, and Revision v3.0.2, plus the ovarian cancer resource reference.SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.